Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

@article{Schneider2006EffectivenessOA,
  title={Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.},
  author={Lon S Schneider and Pierre N. Tariot and Karen Stevens Dagerman and Sonia M. Davis and John K. Hsiao and M. Saleem Ismail and Barry Lebowitz and Constantine G Lyketsos and Jeffrey Michael Ryan and T. Scott Stroup and David L. Sultzer and Daniel Weintraub and Jeffrey A. Lieberman},
  journal={The New England journal of medicine},
  year={2006},
  volume={355 15},
  pages={
          1525-38
        }
}
BACKGROUND Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, aggression, and agitation in patients with Alzheimer's disease, but their benefits are uncertain and concerns about safety have emerged. We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease. METHODS In this 42-site, double-blind, placebo-controlled trial, 421 outpatients with Alzheimer's disease and psychosis, aggression, or agitation were randomly… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 75 CITATIONS, ESTIMATED 36% COVERAGE

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 5 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006

Evaluating a safety signal in the postmarking period : cerebrovascular adverse events associated with risperidone and olanzapine

LS Schneider, KS Dagerman, P Insel
  • Presented at the 17 th Annual Meeting of the American Association for Geriatric Psychiatry
  • 2004

Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.

  • CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2004

Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background.

  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2002

Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.

  • CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • 2002

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.

  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2001